Skip to content

A study where we compare the new treatment protocol with the standard one used in the management of acute exacerbation of asthma.

Comparison between nebulized magnesium sulphate with salbutamol and nebulized salbutamol alone as a first line management for acute exacerbation of asthma in pediatrics population- A Randomised control trial - NIL

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/08/092538
Enrollment
80
Registered
2025-08-06
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J22- Unspecified acute lower respiratory infection

Interventions

Intervention1: Nebulisation with magnesium sulphate: 1 group will be nebulized with salbutamol alone @0.07 mg/kg 3 times for the first hour and other will be nebulized with salbutamol 0.07 mg/kg and m

Sponsors

INDIRA GANDHI MEDICAL COLLEGE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children between the ages of 5-17 years of age diagnosed as acute exacerbation of asthma. And have an initial pediatric respiratory assessment measure (PRAM) more than 4. Or is a known case of childhood asthma or past history of similar episodes relieved with bronchodilator therapy or already on Controller therapy or family history of asthma/ atopy/ nebulisations or personal history of atopic dermatitis/ food allergy/ allergic rhinitis.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The primary outcome is the difference in improvement of PEFR between the 2 groupsTimepoint: The primary outcome is the difference in PEFR at 0, 20, 60 min and 24 hrs

Secondary

MeasureTime frame
Improvement in PRAM score at 0 min, 20 min, 60 min, 24 hrs Requirement of iv magnesium sulphate. Duration of hospital stayTimepoint: 0 min, 20 min, 60 min and 24 hrs

Countries

India

Contacts

Public ContactBhanupriya Sharma

IGMC shimla

dr438raj@gmail.com08219160813

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026